The Institute of Hematology & Blood Diseases Hospital in China is conducting a single center prospective study to look at the efficacy and safety of using a drug called Obinutuzumab in the treatment of ITP for children between the ages of 12-18 years. Obinutuzumab is another type of monoclonal antibody and is being evaluated for its impact among pediatric ITP patients who have failed to response to first-line therapies, particularly to steroid treatment. Participants must also be in good health.
China
Actively Recruiting